A retrospective cohort study assessing the efficacy of maintenance therapy with newly diagnosed stage III/IV Ovarian Cancer patients who received first-line platinum-based chemotherapy
Latest Information Update: 06 Sep 2023
Price :
$35 *
At a glance
- Drugs Bevacizumab (Primary) ; Olaparib (Primary) ; Paclitaxel (Primary) ; Rucaparib (Primary) ; Antineoplastics
- Indications Ovarian cancer
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 12 Jul 2021 New trial record
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology